

Comparison of Platelet Rich Fibrin over Platelet Rich Plasma: A Current Review

ABSTRACT

Clinical applications have been made of platelet rich fibrin (PRF), a platelet concentrate that can promote tissue regeneration. It's interesting to note that despite numerous techniques being put forth, not much information has been found about the final cell counts after centrifugation. There are several centrifuges that are commercially available with their corresponding procedures using a new technique for cell quantification. Platelet concentrates, such as platelet-rich fibrin (PRF) and platelet-rich plasma (PRP), have been used extensively as a scaffold to promote tissue regeneration in numerous medical specialties. PRP was initially presented as a specialized restorative technique meant to concentrate entire blood platelets. The aim of this study was to compare the effectiveness of PRP and PRF.

Keywords: [Platelet Concentrates, Platelet Rich Plasma, Platelet Rich Fibrin, Secretory Proteins, Leucocyte-poor Platelet Rich plasma, Advanced Rich Plasma Plus]

1. INTRODUCTION

Platelets are fragments of megakaryocytes' cytoplasm released by Bone marrow. More than 30 bioactive proteins are present in them, many of which are essential for tissue repair or hemostasis. All wound healing processes are initiated by seven basic protein growth factors that are actively released by platelets [1]. In regenerative medicine, various platelet concentrates have been employed as surgical adjuvants to promote tissue regeneration and wound healing. It's even unclear exactly how a wound heals, while it's commonly known that platelets are involved in inflammation, angiogenesis, homeostasis, and tissue regeneration. Platelets have bioactive factors (growth factors, immune system messengers, and enzymes) are extracted from peripheral blood [2]. Additionally, the platelets' growth factors promote the need for and development of mesenchymal stem cells as well as other target cells [3].

In PRP growth factors are released by the activated platelets and are essential for the quick healing of wounds [4, 5]. PRP functions as both a hemostatic and an adhesive graft substance [5]. The platelet concentration in PRP varies between 500,000 and 1 million μL . PRP also contains vitronectin, fibronectin, and fibrin, three blood proteins that are known to function as cell adhesion agents. After activation, the platelet granules fuse to the cell membrane (a process known as degranulation), where histones and carbohydrate side chains are added to the secretory proteins (such as TGF- β , PDGF, and so forth) to make them bioactive [6]. Following their secretion, the active proteins attach to target cells' transmembrane receptors, including mesenchymal stem cells, osteoblasts, fibroblasts, endothelial cells, and epidermal cells. After these agonists bind to trans membrane receptors, they activate an intracellular signal protein, which triggers the expression of a gene sequence that controls the growth of cells, the development of matrices, the synthesis of collagen, the production of osteoid tissue, and other processes leading to tissue regeneration and repair[7].

When comparing PRF to PRP, the main benefits of PRF are its ease of use, affordability, lack of biochemical processing of patient blood samples, immune system support, and, because of its lower degree of polymerization, somewhat better potential for wound healing [8]. Furthermore, because PRF is more effective at promoting cell migration and proliferation and lacks bovine thrombin and anticoagulants, it carries fewer dangers than PRP [9].

2. PLATELET CONCENTRATES

Platelet concentrates were only utilized to stop bleeding when the patient had significant thrombocytopenia. Because of the enormous numbers of growth factors that are stored inside platelets and the adhesive qualities of fibrin matrix, which is the final product of coagulation cascade, there has been an increase in the application of platelet concentrates for the regeneration of hard and soft tissues. Fibrin glue or sealant was first used in the production of platelet concentrates to promote tissue repair [10].

According to the study conducted by Bielecki et al classification of platelet concentrate based on two essential criteria: the presence of cell content (mostly leukocytes) and the fibrin architecture. This division made it possible to classify the products into four major families [11]. Leukocyte-Poor Platelet-Rich Plasma (P-PRP) products are preparations that have a low-density fibrin network following activation but do not contain leukocytes [12]. All of the items in this family, by definition, can be utilized as liquid solutions or as activated gel. As a result, it can be injected (for instance, in sports medicine) or applied (much like fibrin glues) to a skin incision or suture while it gels [13].

2.1. Platelet-Rich Plasma

Platelet-rich plasma (PRP) has been extensively employed as a first generation platelet concentrate. Leukocyte-Poor Platelet-Rich Plasma (P-PRP) has a low-density fibrin network following activation but do not contain leukocytes [14]. Platelet-rich plasma (PRP) has been extensively employed as a first generation platelet concentrate [15]. Leukocyte-and Platelet-Rich Plasma (L-PRP) are combinations of leukocytes and, following activation, a low-density fibrin network. All of the products in this family, by definition, can be utilized as liquid solutions or in the form of activated gel, just like the P-PRP [16]. Using thrombin, calcium, or other physiologically safe anticoagulants is frequently necessary throughout the PRP preparation process. These elements may trigger an immunological reaction in addition to having a negative impact on the coagulation process [17]. Leukocyte content in PRP therapy vials varies greatly depending on the PRP preparation equipment. The existence of leukocytes and their contributions to several sub-PRP products, including PRGF, P-PRP, LP-PRP, LR-PRP, P-PRF, and L-PRF, have been hotly contested [18].

Donor plasma is used to create this first bioactive surgical adjuvant, and thrombin and calcium are added to start the polymerization process [19]. Originally made with donor plasma, these adhesives can alternatively be bought commercially or obtained from patients (autologously). The goal of the second-generation platelet concentrate was to eliminate anticoagulants when PRP was developed [20]. The removal of anticoagulants causes blood to clot over time, so the clinician must start centrifuging as soon as blood is collected in order to separate the blood layers before clotting. A fibrin clot is produced in the upper "platelet-rich" layer after centrifugation. Platelets and leukocytes trapped in this fibrin matrix are the typical cells seen within this layer [21].

2.2. Platelet Rich Fibrin

Platelet-Rich Fibrin (PRF) is a different type of platelet concentrate that was created in France because of the preparation's robust fibrin gel polymerization. This method was so plainly distinct from prior PRPs that it was referred to as a "second-generation" platelet concentrate; however, given the lengthy history of platelet concentrate evolution, this phrase is probably not appropriate. These days, people just think of it as one more product family among the other two [22]. It was noted by Bielecki et al. that these platelet concentrations were also connected to different types of circulating cells, especially leukocytes [23].

Results pertaining to the release of growth factors both in vitro and in vivo support the clinical application of PRF [24]. According to Dohan et al.'s in vitro research, PRF has superior healing qualities than PRP [25]. In a similar vein, Wiltfang et al. from several clinical trials have shown that the PRF outperforms the PRP in terms of promising outcomes [7]. According to a study by Kawamura and Urist, PRF serves as a matrix that facilitates the transportation of morphogenetic proteins [8].

Direct stem cell migration, hemostasis, wound healing, bone repair, and graft stabilization are all improved by the highly structured fibrin matrix found in the PRF. Platelet rich-fibrin (PRF) has since been utilized with a better ability to release more growth factors over an extended period of time with superior clinical outcomes in various fields of medicine and dentistry [26]. Leukocyte-Poor Platelet-Rich Fibrin (P-PRF) or pure platelet-rich fibrin, which is a fibrin network with a high density, does not contain leukocytes. These products, by definition, are only available as strongly activated gels; they cannot be injected or applied in the same manner as conventional fibrin glues [27]. For other purposes, though, they can be treated as a true solid material due to their robust fibrin matrix. Products with leukocytes and a high-density fibrin network are known as leukocyte-platelet-rich fibrin (L-PRF) [28].

3. PRF PRODUCTION AND CLASSIFICATION

Choukroun et al. in 2001 conducted a study while collecting of 10 ml of blood in glass-coated plastic tubes without the use of an anticoagulant and then centrifuged at 2,700 rpm (around 400 g) for 12 minutes. These acquired PRFs are commonly referred to as leukocyte and PRF (L-PRF) or Choukroun's PRF. The PRF procedure has changed a lot during the past few years. These procedures produced a range of compounds with distinct biological properties and possible applications [29, 30].

Gaanati S et al. suggested that lowering the centrifugation speed could avoid cell loss and boost the quantity of leukocytes in the PRF matrix because it is well known that strong centrifugal forces cause cells to settle to the bottom of the tube. Glass-based vacuum tubes with a reduced centrifugal force of 1,500 rpm (230 g) for 14 minutes were used to generate Advanced PRF (A-PRF). It has also been suggested that A-PRF can be produced using the same centrifugation period of 14 minutes, but at a speed of 1,300 rpm (200 g) [31]. When compared to the L-PRF, the obtained A-PRF had a higher total cell viability percentage. Among these, a rise in platelets, lymphocytes, and neutrophils was noted [32]. Immune cells have an impact on macrophage maturation and differentiation [33]. Thanks mostly to the growth factors that macrophages produce, this may result in the regeneration of soft tissues and bone [34].

Fujioka-Kobayashi M et al. discussed that advanced rich plasma plus (A-PRF+) was created after further modifications to the A-PRF technique. The amount of cells trapped in The PRF

matrix is directly influenced by the centrifugation force; research has attempted to lower the centrifugal time and, consequently, the total force that could cause cell loss[35].

A-PRF+ was prepared by reducing the centrifugal time and speed to 8 min and 1,300 rpm (200 g) [36]. Kobayashi et al. comparing the obtained A-PRF+ to the A-PRF and L-PRF, analysis shows a significantly higher amount of released growth factors (TGF- β 1, VEGF, PDGF, EGF, and IGF1)[36]. When compared to L-PRF, the total amount of secreted growth factors (TGF- β 1, VEGF, PDGF, EGF, and IGF1) was much larger in A-PRF[37]. Nevertheless, as was recently reviewed, some earlier research indicated that A-PRF released fewer growth factors than L-PRF. Because of the slower centrifugation speed and duration, there may be more leukocytes caught in the fibrin mesh, which could explain the observed increase in growth factor release. [38].

One of PRF's primary drawbacks over PRP is that it can only be obtained in gel form, which makes it unsuitable for injection. Injectable PRF (i-PRF), a liquid variant of PRF, has a new procedure thanks to recent research. In order to create this injectable version of PRF, blood without an anticoagulant is used, and plastic tubes without any coatings are centrifuged for three minutes at 700 rpm (60 g) [39]. Plasma, clotting factors, and platelets make up the yellow layer at the top of the tube, and this process allows the separation of blood components during the first few minutes of spinning. When the layer is ready to be applied in injectable form, it can be aspirated with ease [40]. Higher early growth factor release was shown by the growth factor release study, whereas greater long-term release of PDGF-AA, PDGF-AB, EGF, and IGF-1 at 10 days was shown by PRF. Moreover, in comparison to PRP, i-PRF demonstrated higher mRNA levels of TGF- β at 7 days, PDGF at 3 days, and collagen1 expression at both 3 and 7 days [41].

A variety of PRF protocol adjustments have been suggested in recent years. One of them is titanium-PRF (T-PRF), which is made using medical-grade titanium tubes and involves centrifuging a blood sample for 12 minutes at 2,800 rpm (around 400 g)[42]. The same scientists also show that the T-PRF fibrin network is thicker and covers a greater area than the L-PRF fibrin network, suggesting that T-PRF may remain in the tissues for a little while longer [43]. Concentrated growth factors (CGFs) are an alternative kind of PRF that may be a variation of the same platelet concentrate. They are mostly based on the i-PRF production process. The authors suggested utilizing a specialized centrifuge to centrifuge blood samples at different speeds (between 2,400 and 3,300 rpm) and for a predetermined amount of time (in plastic tubes without coatings). The idea behind both variations is to separate platelets and plasma at the tube's top so that the latter can be extracted and utilized as an injectable [44].

3.1. USES OF PRP AND PRF

Growth factors (GFs) are essential for angiogenesis, differentiation, migration, and cell proliferation. Due to their high GF content, autologous platelet concentrates (APCs) are particularly well suited for face rejuvenation and periodontal regeneration. Platelet-rich plasma (PRP), platelet-rich fibrin (PRF), and concentrated growth factor (CGF) approaches are the three primary generations of APCs that are described. PRP is a legitimate adjuvant for a variety of oral and dental surgical treatments [45]. Following tooth extractions, PRP in the alveolar socket can undoubtedly enhance soft tissue healing and have a favorable impact on bone regeneration.

According to Ferrara N., the α -granules of PRP, there are plethora of anti-angiogenic proteins and cytokines (such as TSP-1, plasminogen activation inhibitor-1, and PF4) as well as pro-

angiogenic growth factors that work to target the release of particular components involved in blood vessel creation. Consequently, the activation of particular cell surface receptors may characterize the function of PRP in regulating angiogenic regulation, with TGF- β evoking both pro- and anti-angiogenic responses [46]. In addition to conducting a thorough analysis of PRP and platelet poor plasma (PPP) as biological treatments for skeletal muscle repair, Oberlohr and colleagues also investigated the function of cell senescence in reduced muscle regeneration. By focusing on SASP-specific cell markers and other variables that contribute to the development of fibrosis, they hypothesized that PRP or PPP treatment for skeletal muscle healing will be predicated on the customization of biological parameters [47].

According to a study by Georgakopoulos et al., the placement of PRP surrounding a dental implant enhances bone growth, which enhances implant stability and improves treatment outcomes [48]. Additionally, a study by Thor et al. emphasizes how using PRP increases implant survival rates and improves implant stability. Early implant stability and loading are demonstrated by the PRP. PRP's effectiveness in implant dentistry is still somewhat restricted. To determine the therapeutic relevance of the outcome metrics associated with PRP and implants, more clinical research is needed [49]. Variations in PRP preparation techniques and significant variations in baseline platelet counts among patients may make it impossible to regulate the correlation between platelet dose, concentration, and the concentration of released platelet bioactive growth factors and agents [50, 51]. In immunomodulatory processes and tissue repair mechanisms, monocytes and macrophages are important players. Neutrophils may or may not be important in PRP. The optimal PRP formulation for achieving successful treatment outcomes for joint OA can be LP-PRP [52].

A promising new therapy option for skin rejuvenation is I-PRF/C-PRF. These PRF products can be applied as an anti-aging treatment and to improve the tone and texture of the skin, as well as spots and scars left by acne. These can also be used to improve the skin on the hands, neck, chest, tear trough, nasolabial folds, and perioral lines. Via a population of mesenchymal stem cells, leukocytes perform vital markedly increased cell proliferation. Regenerative tasks such as promoting the growth of fibroblasts, enhancing anti-inflammatory effects, promoting angiogenesis, and depositing procollagen protein to rebuild the extracellular matrix [53]. The platelets in C-PRP are expected to promote immunomodulatory responses, chemotactic cell migration, mesenchymal and neurotrophic factor production, and cell proliferation [54]. Studies have also revealed that, in comparison to control and PRP (200% increase), skin fibroblasts move over 350% more in fluid-PRF. For face rejuvenation also Nacopoulos and Vesala suggested a combination of A-PRF and I-PRF matrices in Cleopatra technique [55]. Adipose stem cells (ASCs) benefit greatly from PRF as an adjuvant because it encourages ASC differentiation, proliferation, and paracrine function. Due to its benefits in avoiding immunologic rejection, ease of manufacture, and lack of problems, PRF has been utilized extensively in clinical practice to enhance the effectiveness of cell-assisted lipotransfer (CAL) and wound repair by ASCs [56].

5. CONCLUSION

Although the preliminary research findings are encouraging, more investigation is required into the application of PRF and PRP. Because PRF and PRP are natural materials, they are biocompatible and biodegradable. As a result, nothing unnecessary is wasted in the process of getting them. They don't trigger allergic reactions because of their biocompatibility. Because of this, platelet concentrates have a lot of potential applications in medicine, including dentistry. Since no creature would reject a product that causes allergies, these qualities are currently the most sought-after ones. PRP and PRF are hence universal products that can be used to treat a wide range of ailments.

Disclaimer (Artificial intelligence)

Option 1:

Author(s) hereby declare that NO generative AI technologies such as Large Language Models (ChatGPT, COPILOT, etc) and text-to-image generators have been used during writing or editing of manuscripts.

Option 2:

Author(s) hereby declare that generative AI technologies such as Large Language Models, etc have been used during writing or editing of manuscripts. This explanation will include the name, version, model, and source of the generative AI technology and as well as all input prompts provided to the generative AI technology

Details of the AI usage are given below:

- 1.
- 2.
- 3.

REFERENCES

1. Mihaylova Z, Mitev V, Stanimirov P, Isaeva A, Gateva N, Ishkitiev N. Use of platelet concentrates in oral and maxillofacial surgery: an overview. *Acta Odontol Scand.* 2017; 75(1):1–11.
2. Marques LF, Stessuk T, Camargo IC, Sabeh Junior N, dos Santos L, et al. Platelet-rich plasma (PRP): methodological aspects and clinical applications. *Platelets.* 2015;26(2):101–13.
3. Frey miller EG, and Marx R. Platelet-rich plasma: Evidence to support its use [2] (multiple letters). *J Oral Maxillofac Surg.* 2004; 62 1046–1048.
4. Ehrenfest DMD, Bielecki T, Corso MD, et al. Shedding light in the controversial terminology for platelet-rich products: Platelet-rich plasma (PRP), platelet-rich fibrin (PRF), platelet-leukocyte gel (PLG), preparation rich in growth factors (PRGF), classification and commercialism. *J Biomed Mater Res A.* 2010; 95 1280–1282.
5. Priya N. Platelet rich plasma: clinical applications of PRP in dentistry. *IOSR J Dent Med Sci.* 2014; 13 41–43.

6. Miron RJ, Fujioka-Kobayashi M, Bishara M, et al. Platelet-rich fibrin and soft tissue wound healing: a systematic review. *Tissue Eng Part B Rev*, 2017; 23 83–99.
7. Anitua E, Murias-Freijo A, Alkhraisat MH, et al. Clinical, radiographical, and histological outcomes of plasma rich in growth factors in extraction socket: A randomized controlled clinical trial. *Clin Oral Investig*, 2015; 19 589–600.
8. Kobayashi E, Flückiger L, Fujioka-Kobayashi M, Sawada K, Sculean A, Schaller B, et al. Comparative release of growth factors from PRP, PRF, and advanced-PRF. *Clin Oral Investig*. 2016;20(9):2353–60
9. Knezevic NN, Candido KD, Desai R, Kaye AD. Is platelet-rich plasma a future therapy in pain management? *Med Clin North Am*. 2016; 100(1):199–217.
10. Tözüm TF and Demiralp B. Platelet-rich plasma: a promising innovation in dentistry. *J Can Dent Assoc*, 2003; 69: 664.
11. Borie E, Oliví DG, Orsi IA, et al. Platelet-rich fibrin application in dentistry: a literature review. *Int J Clin Exp Med*, 2015; 8 7922–7929.
12. Bielecki T, Dohan Ehrenfest DM. Platelet-rich plasma (PRP) and Platelet-Rich Fibrin (PRF): surgical adjuvants, preparations for in situ regenerative medicine and tools for tissue engineering. *Curr Pharm Biotechnol*. 2012; 13:1121–1130.
13. Dohan Ehrenfest DM, Rasmusson L, Albrektsson T. Classification of platelet concentrates: from pure platelet-rich plasma (P-PRP) to leucocyte- and platelet-rich fibrin (L-PRF) *Trends Biotechnol*. 2009; 27:158–167.
14. Cieslik-Bielecka A, Choukroun J, Odin G, Dohan Ehrenfest DM. L-PRP/L-PRF in esthetic plastic surgery, regenerative medicine of the skin and chronic wounds. *Curr Pharm Biotechnol*. 2012; 13:1266–1277.
15. Anitua E, Sanchez M, Orive G, Andia I. The potential impact of the preparation rich in growth factors (PRGF) in different medical fields. *Biomaterials*. 2007; 28:4551–4560.
16. Puzzitiello R.N., Patel B.H., Forlenza E.M., Nwachukwu B.U., Allen A.A., Forsythe B., Salzler M.J. Adverse Impact of Corticosteroids on Rotator Cuff Tendon Health and Repair: A Systematic Review of Basic Science Studies. *Arthrosc. Sports Med. Rehabil*. 2020;2:e161–e169.
17. Everts PA, Hoffmann J, Weibrich G, et al. Differences in platelet growth factor release and leucocyte kinetics during autologous platelet gel formation. *Transfus Med*. 2006; 16:363–368.
18. Everts PA, Hoogbergen MM, Weber TA, Devilee RJ, van Monfort G, de Hingh IH. Is the use of autologous platelet-rich plasma gels in gynecologic, cardiac, and general, reconstructive surgery beneficial? *Curr Pharm Biotechnol*. 2012; 13:1163–1172.
19. Lana J.F., Macedo A., Ingrao I.L.G., Huber S.C., Santos G.S., Santana M.H.A. Leukocyte-rich PRP for knee osteoarthritis: Current concepts. *J. Clin. Orthop. Trauma*. 2019; 10:S179–S182.

20. Narayanaswamy R., Sha I. Arthroscopic Meniscal Repair with Second-Generation Platelet-Rich Fibrin Clot Augmentation. *Arthrosc. Tech.* 2022;11:e1569–e1575.
21. Marx RE. Platelet-rich plasma: Evidence to support its use. *J Oral Maxillofac Surg.* 2004; 62:489–96.
22. Wang Z., Han L., Sun T., Wang W., Li X., Wu B. Preparation and Effect of Lyophilized Platelet-Rich Fibrin on the Osteogenic Potential of Bone Marrow Mesenchymal Stem Cells in Vitro and in Vivo. *Heliyon.* 2019;5:e02739.
23. Dohan DM, Choukroun J, Diss A, et al. Platelet-rich fibrin (PRF): a second-generation platelet concentrate. Part I: technological concepts and evolution. *Oral Surg Oral Med Oral Pathol Oral Radiol Endod.* 2006;101:e37–44.
24. Cieslik-Bielecka A, Gazdzik TS, Bielecki TM, Cieslik T. Why the platelet-rich gel has antimicrobial activity? *Oral Surg Oral Med Oral Pathol Oral Radiol Endod.* 2007; 103:303–305.
25. Cieslik-Bielecka A, Bielecki T, Gazdzik TS, Arendt J, Krol W, Szczepanski T. Autologous platelets and leukocytes can improve healing of infected high-energy soft tissue injury. *Transfus Apher Sci.* 2009; 41:9–12.
26. Dohan Ehrenfest DM, de Peppo GM, Doglioli P, Sammartino G. Slow release of growth factors and thrombospondin-1 in Choukroun's platelet-rich fibrin (PRF): a gold standard to achieve for all surgical platelet concentrates technologies. *Growth Factors.* 2009; 27:63–69.
27. Dohan DM, Choukroun J, Diss A, et al. Platelet-rich fibrin (PRF): a second-generation platelet concentrate. Part II: platelet-related biologic features. *Oral Surg Oral Med Oral Pathol Oral Radiol Endod.* 2006;101:e45–50.
28. Weibrich G, Kleis WK, Kunz-Kostomanolakis M, Loos AH, Wagner W. Correlation of platelet concentration in platelet-rich plasma to the extraction method, age, sex, and platelet count of the donor. *Int J Oral Maxillofac Implants.* 2001; 16:693–699.
29. Gibble JW, Ness PM. Fibrin glue: the perfect operative sealant? *Transfusion.* 1990; 30:741–747.
30. Dohan DM, Choukroun J, Diss A, Dohan SL, Dohan AJ, Mouhyi J, et al. Platelet-rich fibrin (PRF): a second-generation platelet concentrate. Part I: technological concepts and evolution. *Oral Surg Oral Med Oral Pathol Oral Radiol Endod.* 2006;101(3):e37–44.
31. Dohan Ehrenfest DM, Rasmusson L, Albrektsson T. Classification of platelet concentrates: from pure platelet-rich plasma (P-PRP) to leucocyte- and platelet-rich fibrin (L-PRF). *Trends Biotechnol.* 2009;27(3):158–67.
32. Ghanaati S, Booms P, Orlowska A, Kubesch A, Lorenz J, Rutkowski J, et al. Advanced platelet-rich fibrin: a new concept for cell-based tissue engineering by means of inflammatory cells. *J Oral Implantol.* 2014;40(6):679–89.
33. Jameson CA. Autologous platelet concentrates for the production of platelet gel. *Lab Med.* 2007;38(1):39–42.

34. Gurtner GC, Werner S, Barrandon Y, Longaker MT. Wound repair and regeneration. *Nature*. 2008;453(7193):314–21.
35. Barbon S, Stocco E, Macchi V, Contran M, Grandi F, Borean A, et al. Platelet-rich fibrin scaffolds for cartilage and tendon regenerative medicine: from bench to bedside. *Int J Mol Sci*. 2019; 20(7):1701.
36. Fujioka-Kobayashi M, Miron RJ, Hernandez M, Kandalam U, Zhang Y, Choukroun J. Optimized platelet-rich fibrin with the low-speed concept: growth factor release, biocompatibility, and cellular response. *J Periodontol*. 2017; 88(1):112–21.
37. Kobayashi E, Flückiger L, Fujioka-Kobayashi M, Sawada K, Sculean A, Schaller B, et al. Comparative release of growth factors from PRP, PRF, and advanced-PRF. *Clin Oral Investig*. 2016; 20(9):2353–60.
38. Sinder BP, Pettit AR, McCauley LK. Macrophages: their emerging roles in bone. *J Bone Miner Res*. 2015; 30(12):2140–9.
39. Shah R, Thomas MGT, Mehta R, A DS. Update on the protocols and biologic actions of platelet rich fibrin in dentistry. *Eur J Prosthodont Restor Dent*. 2017; 25(2):64–72.
40. Mourão CF, Valiense H, Melo ER, Mourão NB, Maia MD. Obtention of injectable platelets rich-fibrin (i-PRF) and its polymerization with bone graft: technical note. *Rev Col Bras Cir*. 2015; 42(6):421–3.
41. Bowen RA, Remaley AT. Interferences from blood collection tube components on clinical chemistry assays. *Biochem Med*. 2014;24(1):31–44.
42. Miron RJ, Fujioka-Kobayashi M, Hernandez M, Kandalam U, Zhang Y, Ghanaati S, et al. Injectable platelet rich fibrin (i-PRF): opportunities in regenerative dentistry? *Clin Oral Investig*. 2017;21(8):2619–27.
43. Tunalı M, Özdemir H, Küçükodacı Z, Akman S, Yaprak E, Toker H, et al. A novel platelet concentrate: titanium-prepared platelet-rich fibrin. *Biomed Res Int*. 2014;2014:209548.
44. Sohn DS, Huang B, Kim J, Park WE, Park CC. Utilization of autologous concentrated growth factors (CGF) enriched bone graft matrix (sticky bone) and CGF-enriched fibrin membrane in implant dentistry. *J Implant Advanced Clin Dent*. 2015;7(10):11–8.
45. Sohn DS, Huang B, Kim J, Park WE, Park CC. Utilization of autologous concentrated growth factors (CGF) enriched bone graft matrix (sticky bone) and CGF-enriched fibrin membrane in implant dentistry. *J Implant Advanced Clin Dent*. 2015;7(10):11–8.
46. Cakir S., Gultekin B.A., Karabagli M., Yilmaz T.E., Cakir E., Guzel E.E., Yalcin S., Mortellaro C., Mijiritsky E. Histological Evaluation of the Effects of Growth Factors in a Fibrin Network on Bone Regeneration. *J. Craniofacial Surg*. 2019;30:1078–1084.
47. Ferrara N. The Role of the VEGF Signaling Pathway in Tumor Angiogenesis. In: Marmé D., editor. *Tumor Angiogenesis: A Key Target for Cancer Therapy*. Springer International Publishing; Cham, Switzerland: 2019. pp. 211–226.

48. Oberlohr V., Lengel H., Hambright W.S., Whitney K.E., Evans T.A., Huard J. Biologics for Skeletal Muscle Healing: The Role of Senescence and Platelet-Based Treatment Modalities. *Oper. Tech. Sports Med.* 2020;28:150754.
49. Georgakopoulos I, Tsantis S, Georgakopoulos P, et al. The impact of platelet rich plasma (PRP) in osseointegration of oral implants in dental panoramic radiography: texture based evaluation. *Clin Cases Miner Bone Metab*, 2014; 11 59–66.
50. Thor A, Wannfors K, Sennerby L, et al. Reconstruction of the severely resorbed maxilla with autogenous bone, platelet-rich plasma, and implants: 1-year results of a controlled prospective 5-year study. *Clin Implant Dent Relat Res*, 2005; 7 209–220.
51. Gentile P., Calabrese C., De Angelis B., Dionisi L., Pizzicanella J., Kothari A., De Fazio D., Garcovich S. Impact of the Different Preparation Methods to Obtain Autologous Non-Activated Platelet-Rich Plasma (A-PRP) and Activated Platelet-Rich Plasma (AA-PRP) in Plastic Surgery: Wound Healing and Hair Regrowth Evaluation. *Int. J. Mol. Sci.* 2020; 21:431.
52. Samadi P., Sheykhasan M., Khoshinani H.M. The Use of Platelet-Rich Plasma in Aesthetic and Regenerative Medicine: A Comprehensive Review. *Aesthetic Plast. Surg.* 2018; 43:803–814.
53. The GRIP (Groupe de Recherche sur les Injections de PRP, PRP Injection Research Group) Eymard P.A., Ornetti P., Maillot J., Noel É., Adam P., Legré-Boyer V., Boyer T., Allali F., Gremeaux V., et al. Intra-articular injections of platelet-rich plasma in symptomatic knee osteoarthritis: A consensus statement from French-speaking experts. *Knee Surg. Sports Traumatol. Arthrosc.* 2020.
54. Xu J., Gou L., Zhang P., Li H., Qiu S. Platelet-rich plasma and regenerative dentistry. *Aust. Dent. J.* 2020;65:131–142.
55. Nacopoulos C, Vesala A-M. Lower facial regeneration with a combination of platelet-rich fibrin liquid matrices based on the low speed centrifugation concept-Cleopatra technique. *J Cosmet Dermatol.* 2020; 19: 185–9.
56. Shivashankar V.Y., Johns D.A., Maroli R.K., Sekar M., Chandrasekaran R., Karthikeyan S., Renganathan S.K. Comparison of the effect of PRP, PRF and induced bleeding in the revascularization of teeth with necrotic pulp and open apex: A triple blind randomized clinical trial. *J. Clin. Diagn. Res.* 2017;11:ZC34–ZC39.
57. Panda S., Doraiswamy J., Malaiappan S., Varghese S.S., Del Fabbro M. Additive effect of autologous platelet concentrates in treatment of intrabony defects: A systematic review and meta-analysis. *J. Investig. Clin. Dent.* 2016; 7:13–26.